PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study

Detalhes bibliográficos
Autor(a) principal: KOTZE,Paulo Gustavo
Data de Publicação: 2014
Outros Autores: ALBUQUERQUE,Idblan Carvalho de, MOREIRA,André da Luz, TONINI,Wanessa Bertrami, OLANDOSKI,Marcia, COY,Claudio Saddy Rodrigues
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de gastroenterologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032014000400284
Resumo: Background Perianal fistulizing Crohn’s disease is one of the most severe phenotypes of inflammatory bowel diseases. Combined therapy with seton placement and anti-TNF therapy is the most common strategy for this condition Objectives The aim of this study was to analyze the rates of complete perianal remission after combined therapy for perianal fistulizing Crohn’s disease. Methods This was a retrospective observational study with perianal fistulizing Crohn’s disease patients submitted to combined therapy from four inflammatory bowel diseases referral centers. We analyzed patients’ demographic characteristics, Montreal classification, concomitant medication, classification of the fistulae, occurrence of perianal complete remission and recurrence after remission. Complete perianal remission was defined as absence of drainage from the fistulae associated with seton removal. Discussion A total of 78 patients were included, 44 (55.8%) females with a mean age of 33.8 (±15) years. Most patients were treated with Infliximab, 66.2%, than with Adalimumab, 33.8%. Complex fistulae were found in 52/78 patients (66.7%). After a medium follow-up of 48.2 months, 41/78 patients (52.6%) had complete perianal remission (95% CI: 43.5%-63.6%). Recurrence occurred in four (9.8%) patients (95% CI: 0.7%-18.8%) in an average period of 74.8 months. Conclusions Combined therapy lead to favorable and durable results in perianal fistulizing Crohn’s disease.
id IBEPEGE-1_c41971518c8471a60213595060358cfa
oai_identifier_str oai:scielo:S0004-28032014000400284
network_acronym_str IBEPEGE-1
network_name_str Arquivos de gastroenterologia (Online)
repository_id_str
spelling PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational studyCrohn’s diseaseTumor necrosis factor-alphaRectal fistula. Background Perianal fistulizing Crohn’s disease is one of the most severe phenotypes of inflammatory bowel diseases. Combined therapy with seton placement and anti-TNF therapy is the most common strategy for this condition Objectives The aim of this study was to analyze the rates of complete perianal remission after combined therapy for perianal fistulizing Crohn’s disease. Methods This was a retrospective observational study with perianal fistulizing Crohn’s disease patients submitted to combined therapy from four inflammatory bowel diseases referral centers. We analyzed patients’ demographic characteristics, Montreal classification, concomitant medication, classification of the fistulae, occurrence of perianal complete remission and recurrence after remission. Complete perianal remission was defined as absence of drainage from the fistulae associated with seton removal. Discussion A total of 78 patients were included, 44 (55.8%) females with a mean age of 33.8 (±15) years. Most patients were treated with Infliximab, 66.2%, than with Adalimumab, 33.8%. Complex fistulae were found in 52/78 patients (66.7%). After a medium follow-up of 48.2 months, 41/78 patients (52.6%) had complete perianal remission (95% CI: 43.5%-63.6%). Recurrence occurred in four (9.8%) patients (95% CI: 0.7%-18.8%) in an average period of 74.8 months. Conclusions Combined therapy lead to favorable and durable results in perianal fistulizing Crohn’s disease. Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE. 2014-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032014000400284Arquivos de Gastroenterologia v.51 n.4 2014reponame:Arquivos de gastroenterologia (Online)instname:Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologiainstacron:IBEPEGE10.1590/S0004-28032014000400004info:eu-repo/semantics/openAccessKOTZE,Paulo GustavoALBUQUERQUE,Idblan Carvalho deMOREIRA,André da LuzTONINI,Wanessa BertramiOLANDOSKI,MarciaCOY,Claudio Saddy Rodrigueseng2015-01-09T00:00:00Zoai:scielo:S0004-28032014000400284Revistahttp://www.scielo.br/aghttps://old.scielo.br/oai/scielo-oai.php||secretariaarqgastr@hospitaligesp.com.br1678-42190004-2803opendoar:2015-01-09T00:00Arquivos de gastroenterologia (Online) - Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologiafalse
dc.title.none.fl_str_mv PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
title PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
spellingShingle PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
KOTZE,Paulo Gustavo
Crohn’s disease
Tumor necrosis factor-alpha
Rectal fistula.
title_short PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
title_full PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
title_fullStr PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
title_full_unstemmed PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
title_sort PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
author KOTZE,Paulo Gustavo
author_facet KOTZE,Paulo Gustavo
ALBUQUERQUE,Idblan Carvalho de
MOREIRA,André da Luz
TONINI,Wanessa Bertrami
OLANDOSKI,Marcia
COY,Claudio Saddy Rodrigues
author_role author
author2 ALBUQUERQUE,Idblan Carvalho de
MOREIRA,André da Luz
TONINI,Wanessa Bertrami
OLANDOSKI,Marcia
COY,Claudio Saddy Rodrigues
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv KOTZE,Paulo Gustavo
ALBUQUERQUE,Idblan Carvalho de
MOREIRA,André da Luz
TONINI,Wanessa Bertrami
OLANDOSKI,Marcia
COY,Claudio Saddy Rodrigues
dc.subject.por.fl_str_mv Crohn’s disease
Tumor necrosis factor-alpha
Rectal fistula.
topic Crohn’s disease
Tumor necrosis factor-alpha
Rectal fistula.
description Background Perianal fistulizing Crohn’s disease is one of the most severe phenotypes of inflammatory bowel diseases. Combined therapy with seton placement and anti-TNF therapy is the most common strategy for this condition Objectives The aim of this study was to analyze the rates of complete perianal remission after combined therapy for perianal fistulizing Crohn’s disease. Methods This was a retrospective observational study with perianal fistulizing Crohn’s disease patients submitted to combined therapy from four inflammatory bowel diseases referral centers. We analyzed patients’ demographic characteristics, Montreal classification, concomitant medication, classification of the fistulae, occurrence of perianal complete remission and recurrence after remission. Complete perianal remission was defined as absence of drainage from the fistulae associated with seton removal. Discussion A total of 78 patients were included, 44 (55.8%) females with a mean age of 33.8 (±15) years. Most patients were treated with Infliximab, 66.2%, than with Adalimumab, 33.8%. Complex fistulae were found in 52/78 patients (66.7%). After a medium follow-up of 48.2 months, 41/78 patients (52.6%) had complete perianal remission (95% CI: 43.5%-63.6%). Recurrence occurred in four (9.8%) patients (95% CI: 0.7%-18.8%) in an average period of 74.8 months. Conclusions Combined therapy lead to favorable and durable results in perianal fistulizing Crohn’s disease.
publishDate 2014
dc.date.none.fl_str_mv 2014-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032014000400284
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032014000400284
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-28032014000400004
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE.
publisher.none.fl_str_mv Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE.
dc.source.none.fl_str_mv Arquivos de Gastroenterologia v.51 n.4 2014
reponame:Arquivos de gastroenterologia (Online)
instname:Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron:IBEPEGE
instname_str Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
instacron_str IBEPEGE
institution IBEPEGE
reponame_str Arquivos de gastroenterologia (Online)
collection Arquivos de gastroenterologia (Online)
repository.name.fl_str_mv Arquivos de gastroenterologia (Online) - Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia
repository.mail.fl_str_mv ||secretariaarqgastr@hospitaligesp.com.br
_version_ 1754193347077996544